flutamide has been researched along with Impotence in 14 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 9.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| " We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate." | 5.08 | Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997) |
| "Treatment of localized prostate cancer (PC) is controversial." | 2.80 | Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. ( Albertsson, P; Brandberg, Y; Damber, JE; Damm, O; Holmberg, E; Isacsson, U; Lennernäs, B; Ljung, G; Majumder, K; Nilsson, S, 2015) |
| "After disease progression, patients treated with bicalutamide were assigned to castration." | 2.69 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G, 1999) |
| " Hepatic toxicity may limit the long-term use of both drugs." | 2.69 | Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. ( Collette, L; de Reijke, TM; Schröder, FH; Whelan, P, 2000) |
| "Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life." | 1.35 | Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008) |
| ") erections we assessed the dose-response effects of p,p-DDE in comparison to the known androgen receptor antagonist flutamide in acute (0." | 1.31 | Effects of an environmental anti-androgen on erectile function in an animal penile erection model. ( Adams, MA; Brien, SE; Heaton, JP; Racz, WJ, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lennernäs, B | 1 |
| Majumder, K | 1 |
| Damber, JE | 1 |
| Albertsson, P | 1 |
| Holmberg, E | 1 |
| Brandberg, Y | 1 |
| Isacsson, U | 1 |
| Ljung, G | 1 |
| Damm, O | 1 |
| Nilsson, S | 1 |
| Jones, CU | 1 |
| Hunt, D | 1 |
| McGowan, DG | 1 |
| Amin, MB | 1 |
| Chetner, MP | 1 |
| Bruner, DW | 1 |
| Leibenhaut, MH | 1 |
| Husain, SM | 1 |
| Rotman, M | 1 |
| Souhami, L | 1 |
| Sandler, HM | 1 |
| Shipley, WU | 1 |
| Lamb, DS | 1 |
| Denham, JW | 1 |
| Mameghan, H | 1 |
| Joseph, D | 1 |
| Turner, S | 1 |
| Matthews, J | 1 |
| Franklin, I | 1 |
| Atkinson, C | 1 |
| North, J | 1 |
| Poulsen, M | 1 |
| Kovacev, O | 1 |
| Robertson, R | 1 |
| Francis, L | 1 |
| Christie, D | 1 |
| Spry, NA | 1 |
| Tai, KH | 1 |
| Wynne, C | 1 |
| Duchesne, G | 1 |
| Lloyd, A | 1 |
| Penson, D | 1 |
| Dewilde, S | 1 |
| Kleinman, L | 1 |
| Fleshner, NE | 1 |
| Trachtenberg, J | 1 |
| Stevens, MJ | 1 |
| Bell, DR | 1 |
| Blome, SA | 1 |
| Begbie, SD | 1 |
| Brufsky, A | 1 |
| Fontaine-Rothe, P | 1 |
| Berlane, K | 1 |
| Rieker, P | 1 |
| Jiroutek, M | 1 |
| Kaplan, I | 1 |
| Kaufman, D | 1 |
| Kantoff, P | 1 |
| Boccardo, F | 1 |
| Rubagotti, A | 1 |
| Barichello, M | 1 |
| Battaglia, M | 1 |
| Carmignani, G | 1 |
| Comeri, G | 1 |
| Conti, G | 1 |
| Cruciani, G | 1 |
| Dammino, S | 1 |
| Delliponti, U | 1 |
| Ditonno, P | 1 |
| Ferraris, V | 1 |
| Lilliu, S | 1 |
| Montefiore, F | 1 |
| Portoghese, F | 1 |
| Spano, G | 1 |
| Schröder, FH | 1 |
| Collette, L | 1 |
| de Reijke, TM | 1 |
| Whelan, P | 1 |
| Brien, SE | 1 |
| Heaton, JP | 1 |
| Racz, WJ | 1 |
| Adams, MA | 1 |
| Iversen, P | 1 |
| Melezinek, I | 1 |
| Schmidt, A | 1 |
| Pavone-Macaluso, M | 2 |
| Serretta, V | 1 |
| Daricello, G | 1 |
| Pavone, C | 1 |
| Cacciatore, M | 1 |
| Romano, C | 1 |
| Cavallo, N | 1 |
| Rousseau, L | 1 |
| Dupont, A | 1 |
| Labrie, F | 1 |
| Couture, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.[NCT05786742] | 205 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | |||
| A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE[NCT00002597] | Phase 3 | 2,028 participants (Actual) | Interventional | 1994-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Phoenix definition of biochemical failure was used - an increase in the prostate-specific antigen (PSA) level of >2 ng per milliliter above the nadir. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 26.3 |
| Radiation Therapy Alone | 41.1 |
Clinical relapse is defined as local progression or distant metastases. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 15.0 |
| Radiation Therapy Alone | 21.7 |
Disease-free failure is defined as documentation of progression (local progression, distant failure, and biochemical failure) or death from any cause. Disease-free survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 51.7 |
| Radiation Therapy Alone | 39.5 |
Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 95.7 |
| Radiation Therapy Alone | 92.6 |
Failure is defined as documented metastatic disease. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 5.5 |
| Radiation Therapy Alone | 8.0 |
Local progression defined as documented local progression as determined by clinical exam . Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 10.9 |
| Radiation Therapy Alone | 16.1 |
Overall survival (OS) was calculated from randomization to the date of death from any cause and overall survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From date of randomization to 10 years
| Intervention | percentage of patients (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 61.9 |
| Radiation Therapy Alone | 56.8 |
The rate of prostate rebiopsy at two years is defined as the proportion of patients whose results are positive among all eligible patients who had a repeat biopsy at two years. The rate was estimated separately in each arm. (NCT00002597)
Timeframe: From registration to two years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 20.2 |
| Radiation Therapy Alone | 38.9 |
Second biochemical relapse is as defined as follows (after initiation of salvage hormone therapy): A rise in PSA on at least two consecutive cases above the nadir (after initiation of salvage hormone therapy), with the rises in PSA exceeding 1 ng/ml above the nadir; or failure to reach 4 ng/L or less at 18 months. The rates of second biochemical relapse were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years
| Intervention | percentage of participants (Number) |
|---|---|
| Hormone Therapy + Radiation Therapy | 2.7 |
| Radiation Therapy Alone | 6.1 |
2 reviews available for flutamide and Impotence
| Article | Year |
|---|---|
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines; | 2001 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
8 trials available for flutamide and Impotence
| Article | Year |
|---|---|
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cost of Illness; Emotions; Erec | 2015 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi | 2011 |
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, | 2003 |
Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
Topics: Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follicle Stimulating Hormone; Goserelin; | 1994 |
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Fl | 1997 |
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; An | 1999 |
Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
Topics: Aged; Androgen Antagonists; Cyproterone; Erectile Dysfunction; Flutamide; Humans; Male; Middle Aged; | 2000 |
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E | 1990 |
5 other studies available for flutamide and Impotence
| Article | Year |
|---|---|
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavi | 2008 |
Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.
Topics: Aged; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Flutamide; Humans; Luteinizing H | 1993 |
Effects of an environmental anti-androgen on erectile function in an animal penile erection model.
Topics: Androgen Antagonists; Animals; Castration; Dichlorodiphenyl Dichloroethylene; Dose-Response Relation | 2000 |
Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
Topics: Androgen Antagonists; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Humans; Imidazoles | 1991 |
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration.
Topics: Aged; Anilides; Combined Modality Therapy; Drive; Erectile Dysfunction; Flutamide; Humans; Male; Mid | 1988 |